First studies into vaccine efficacy against Omicron spark cautious optimism
By Alexander Bueso
Date: Wednesday 08 Dec 2021
(Sharecast News) - Experts reacted with cautious optimism to the results of the first studies into the efficacy of vaccines against the Omicron variant of Covid-19.
While the new variant did lower vaccine efficacy, the loss was not complete.
A study in South Africa among 14 persons given who were administered two doses of the Pfizer-BioNTech shot revealed a 41-fold reduction in the level of virus-blocking antibodies that it generated, when compared to its efficacy against the strain of SARS-CoV-2 that was dominant when the pandemic began.
According to the lead investigator of the first study, Alex Sigal, the head of research at the Africa Health Research Institute in Durban, a "good" booster was likely to reduce people´s chance of becoming infected, particularly the odds of becoming severely ill.
Furthermore, a second study conducted at Sweden's Karolinska Institute was more optimistic, showing that the fall in antibody count was only slightly greater than in the case of Delta, while a German study yielded a 37-fold reduction in the number of antibodies that were generated.
Sigal reportedly recommended that fully vaccinated individuals receive a booster and that those previously infected should get a shot.
The study conducted by Sigal also revealed that the level of neutralising antibodies among the volunteers who had been vaccinated and who had also suffered a previous bout of Covid-19 were significantly higher, providing reasonable protection against Omicron.
Special promo:
Trading the Forex Market? Visit FXmania.com to get advanced infomation about currencies and the Foreign Exchange
Market.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN